Log in to save to my catalogue

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Intravenous arketamine for treatment-resistant depression: open-label pilot study

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2503197009

Intravenous arketamine for treatment-resistant depression: open-label pilot study

About this item

Full title

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

European archives of psychiatry and clinical neuroscience, 2021-04, Vol.271 (3), p.577-582

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

We aimed to analyze the efficacy and safety of arketamine, the
R
(−)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) 24 h...

Alternative Titles

Full title

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2503197009

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2503197009

Other Identifiers

ISSN

0940-1334

E-ISSN

1433-8491

DOI

10.1007/s00406-020-01110-5

How to access this item